Pyxis Oncology, Inc. ((PYXS)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pyxis Oncology, Inc. is conducting a Phase 1 clinical study titled ‘A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors.’ The study aims to determine the recommended dose of PYX-201 and assess its objective response rate in patients with relapsed or refractory solid tumors, highlighting its potential significance in cancer treatment.
PYX-201, the drug being tested, is administered as an intravenous infusion. It is designed to treat various advanced solid tumors, including head and neck squamous cell carcinoma, triple-negative breast cancer, and other types of advanced solid tumors.
This interventional study is non-randomized with a parallel assignment model and no masking. Its primary purpose is treatment-focused, aiming to evaluate the safety and efficacy of PYX-201 in a controlled setting.
The study began on January 30, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates are not specified, but the last update was submitted on July 31, 2025, indicating ongoing progress.
The update on this study could influence Pyxis Oncology’s stock performance positively, as successful results might enhance investor confidence. The competitive landscape in oncology treatments is robust, with numerous companies vying for breakthroughs in solid tumor therapies.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.